DAFNA Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

DAFNA Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,100	Closed	-$222K	–	91
2022 Q2	$222K	Hold	3,100	–	–	0.06%	85
2022 Q1	$304K	Sell	3,100 -2,500	-45%	-$211K	0.08%	87
2021 Q4	$475K	Hold	5,600	–	–	0.12%	83
2021 Q3	$447K	Hold	5,600	–	–	0.12%	77
2021 Q2	$545K	Hold	5,600	–	–	0.11%	81
2021 Q1	$655K	Sell	5,600 -1,000	-15%	-$117K	0.16%	79
2020 Q4	$734K	Hold	6,600	–	–	0.22%	63
2020 Q3	$784K	Hold	6,600	–	–	0.25%	61
2020 Q2	$747K	Sell	6,600 -7,000	-51%	-$688K	0.22%	67
2020 Q1	$908K	Hold	13,600	–	–	0.38%	54
2019 Q4	$1.24M	Buy	13,600 +7,000	+106%	+$679K	0.43%	54
2019 Q3	$569K	Hold	6,600	–	–	0.21%	67
2019 Q2	$692K	Hold	6,600	–	–	0.26%	64
2019 Q1	$827K	Hold	6,600	–	–	0.36%	58
2018 Q4	$744K	Buy	+6,600	New	+$1.02M	0.37%	54

Other funds holding MDGL

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DAFNA Capital Management's MDGL Position: Q3 2022 in Review

DAFNA Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2022, closing a stake of 3,100 shares — an estimated $222K sold.

DAFNA Capital Management first reported a position in MDGL in Q4 2018 and held it in 15 quarters. The position peaked at $1.24M in Q4 2019. 135 funds tracked by Wall St. Rank hold MDGL as of Q3 2022.

DAFNA Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
DAFNA Capital Management sold 3,100 Madrigal Pharmaceuticals shares in Q3 2022, an estimated $222K.
DAFNA Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 15 quarters.
DAFNA Capital Management's Madrigal Pharmaceuticals position peaked at $1.24M in Q4 2019.
135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2022.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.